VRDN
Viridian Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$22.92
−0.17%Aug 6, 2026, 00:00 UTC
Viridian Therapeutics reported its Q2 2026 financial results, with total revenues of $284,000 and a net loss of $127.1 million.
Jun 30, 2026, 12:30 UTC
Viridian Therapeutics received early FDA approval for Lumvoa, a treatment for thyroid eye disease.
Jun 26, 2026, 22:00 UTC
The U.S. FDA approved Lumvoa (veligrotug-vvze) developed by Viridian Therapeutics for the treatment of thyroid eye disease.
Source: